Brokerages expect that Iradimed Corp (NASDAQ:IRMD) will report earnings per share of $0.06 for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Iradimed’s earnings. Iradimed reported earnings per share of $0.11 during the same quarter last year, which suggests a negative year-over-year growth rate of 45.5%. The company is expected to announce its next quarterly earnings results on Monday, February 5th.
On average, analysts expect that Iradimed will report full-year earnings of $0.19 per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post earnings of $0.25 per share. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Iradimed.
Iradimed (NASDAQ:IRMD) last announced its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.35. Iradimed had a net margin of 6.51% and a return on equity of 4.58%. The company had revenue of $5.69 million during the quarter, compared to analysts’ expectations of $5.60 million. During the same quarter in the prior year, the company earned $0.14 EPS. Iradimed’s revenue was down 25.9% compared to the same quarter last year.
Several brokerages recently issued reports on IRMD. Zacks Investment Research cut shares of Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, December 20th. Credit Suisse Group began coverage on shares of Iradimed in a research note on Monday, November 27th. They set a “buy” rating and a $19.00 price objective for the company. Roth Capital began coverage on shares of Iradimed in a research note on Tuesday, October 31st. They set a “buy” rating and a $16.00 price objective for the company. Finally, ValuEngine raised shares of Iradimed from a “sell” rating to a “hold” rating in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $15.33.
In other Iradimed news, Director Monty K. Allen sold 1,898 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $13.95, for a total value of $26,477.10. Following the transaction, the director now directly owns 9,062 shares in the company, valued at approximately $126,414.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 60.10% of the company’s stock.
Large investors have recently bought and sold shares of the business. Citigroup Inc. boosted its holdings in Iradimed by 50.8% in the 2nd quarter. Citigroup Inc. now owns 16,082 shares of the medical equipment provider’s stock valued at $138,000 after purchasing an additional 5,418 shares during the last quarter. Neuberger Berman Group LLC lifted its holdings in shares of Iradimed by 23.3% in the 2nd quarter. Neuberger Berman Group LLC now owns 18,500 shares of the medical equipment provider’s stock worth $159,000 after acquiring an additional 3,500 shares during the last quarter. Connors Investor Services Inc. lifted its holdings in shares of Iradimed by 10.0% in the 2nd quarter. Connors Investor Services Inc. now owns 33,000 shares of the medical equipment provider’s stock worth $284,000 after acquiring an additional 3,000 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Iradimed in the 1st quarter worth approximately $290,000. Finally, Federated Investors Inc. PA lifted its holdings in shares of Iradimed by 7.5% in the 2nd quarter. Federated Investors Inc. PA now owns 40,400 shares of the medical equipment provider’s stock worth $347,000 after acquiring an additional 2,807 shares during the last quarter. Institutional investors own 13.83% of the company’s stock.
Shares of Iradimed (IRMD) traded down $0.10 during midday trading on Friday, reaching $15.60. 33,822 shares of the company traded hands, compared to its average volume of 38,590. Iradimed has a one year low of $7.85 and a one year high of $15.75. The stock has a market cap of $159.38, a PE ratio of 120.01 and a beta of 1.61.
WARNING: “Iradimed Corp (IRMD) Expected to Post Earnings of $0.06 Per Share” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/27/iradimed-corp-irmd-expected-to-post-earnings-of-0-06-per-share.html.
Iradimed Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Get a free copy of the Zacks research report on Iradimed (IRMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.